We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Promethean | LSE:PTH | London | Ordinary Share | GB00B08H5G38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.125 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:8343H
PPL Therapeutics PLC
21 February 2003
PPL Therapeutics plc ("the Company")
DISCLOSURE OF INTEREST
The Company received notification on 20 February 2003 from Metage Capital
Limited that Metage Funds Limited, have an interest in 12,379,110 Ordinary
shares in the Company, representing 10.43% of the Company's issued share
capital.
Of this total 8,754,110 Ordinary shares are held at Metage Funds Limited's
custodian, Credit Suisse First Boston (Europe) Ltd.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUASNROURUUAR
1 Year Promethean Chart |
1 Month Promethean Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
